A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...

From Pfizer's oncology franchise, I was pleased with the strong sales of Lorbrena, Padcev, Braftovi/Mektovi, and Elrexfio, which helped offset the weak performance of Adcetris and Tukysa.

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

The following are the top rated Health Care stocks according to Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies ...

In 2018, it approved Array’s novel–novel pairing of the BRAF inhibitor encorafenib (Braftovi) with the MEK inhibitor binimetinib (Mektovi) for unresectable or metastatic melanoma with BRAF ...